Effects of combination of vitamin D3,montelukast and budesonide on bronchial asthma and its influence on exhaled nitric oxide and inflammatory factors
Objective To explore the effects of combination of vitamin D3,montelukast and budesonide on bronchial asthma and its influence on exhaled nitric oxide(FeNO)and inflammatory factors.Methods 92 children with bronchial asthma were divided into a control group and an observation group according to random number table,with 46 cases in each group.The control group was treated with montelukast orally and budesonide aerosol inhalation,and the observation group was treated with vitamin D3 orally on the basis of the control group.Children in both groups were compared in terms of clinical efficacy,incidence of adverse reactions,scores of children asthma control test(C-ACT),lung function indicators[forced expiratory volume in one second(FEV1),forced vital capacity(FVC)],exhaled nitric oxide(FeNO),inflammatory factors(interleukin-6,C-reactive protein)and total immunoglobulin E(IgE)before and after treatment.Results After treatment,C-ACT score in both groups was higher than that before treatment,and the observation group had higher C-ACT score of(22.47±2.02)points than(20.16±2.08)points in the control group(P<0.05).After treatment,the forced expiratory volume in one second and forced vital capacity in both groups were higher than those before treatment,and the exhaled nitric oxide was lower than that before treatment;the observation group had forced expiratory volume in one second of(2.53±0.62)L and forced vital capacity of(2.82±0.52)L,which were higher than(1.84±0.53)and(2.12±0.46)L in the control group;the observation group had lower exhaled nitric oxide of(13.78±5.20)ppb than(23.74±4.22)ppb in the control group(P<0.05).After treatment,the interleukin-6,C-reactive protein and total IgE in both groups were lower than those before treatment;the observation group had interleukin-6 of(15.10±5.34)ng/L,C-reactive protein of(9.35±1.04)mg/L,and total IgE of(125.16±18.92)IU/ml,which were lower than(20.18±6.62)ng/L,(10.31±1.05)mg/L,and(158.64±20.16)IU/ml in the control group(P<0.05).The total clinical effective rate of the observation group was 89.13%(41/46),which was significantly higher than 69.57%(32/46)of the control group(P<0.05).There were no obvious adverse reactions during treatment in the two groups.Conclusion The combination of vitamin D3,montelukast and budesonide in the treatment of bronchial asthma can effectively reduce airway inflammation and body hypersensitivity,improve lung function and improve asthma control effect.
万方数据
